Shows
touchPODCASTNavigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY
Listen to multiple myeloma expert Prof. Philippe Moreau review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2025 congresses. Prof. Moreau is then joined by fellow experts Dr Paola Neri and Prof. Hermann Einsele to discuss how these data may apply in clinical practice.
Overview
Data reviews with Prof. Moreau
Expert panel discussions with Prof. Moreau, Dr Neri and Prof. Einsele on the themes below
2025-07-091h 09
Multiple Myeloma HubWhat are the future perspectives for anti-CD38 mAbs in the treatment of MM?In this interview, Hermann Einsele discusses the future perspectives of anti-CD38 antibodies, highlighting their role in first-line treatment for both transplant-eligible and -ineligible patients as well as applications in the second line and smoldering MM. Einsele also discusses outcomes from key trials and outlines potential combinations of anti-CD38s with emerging therapies, including cereblon E3 ligase modulators (CELMoDs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content o...2025-05-1910 min
Hämatologie ShortcastsDGHO 2024: Multiples Myelom - Neue Leitlinien, Therapieoptionen und ZukunftsperspektivenAuf der Jahrestagung der DGHO sprechen Dr. Richard Schabath und Dr. Stephan Fuhrmann mit Prof. Dr. Hermann Einsele, Direktor der Medizinischen Klinik und Poliklinik II am Uniklinikum Würzburg (UKW), über die aktuell veröffentlichte Leitlinie zum Multiplen Myelom. Sie diskutieren über:- Standards und aktuelle Entwicklungen der Erstlinientherapie- Patientenstratifikation und Algorithmen in der Auswahl der Zweitlinientherapie- Empfehlungen zur Diagnostik- Stellenwert und Entwicklung der immuntherapeutischen Ansätze (CAR T-Zellen, bispezifische Antikörper)- supportive Therapie und Infektionsprophylaxe
Besuchen Sie gerne unsere Website, u...2024-10-2123 minMultiple Myeloma HubInfections associated with bispecific antibodiesDuring the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss key considerations regarding infections associated with bispecific antibodies. Meral Beksaç opened with a presentation reviewing the infectious complications associated with bispecific antibodies, and current treatment algorithms for such infections. Beksaç explored an analysis of infections and parameters of humoral immunity in the MonumenTAL-1 study, the clinical management of infections, and regional differences in access to prophylaxis and treatment for infections. Following her presentation, Beksaç chaired a Q&A session featuring Hermann Einsele, Paul Richardson, Heinz Ludwig, María-Victoria Mateos, Elena Zamagni, an...2024-07-1630 minMultiple Myeloma HubCAR T-cell therapies in clinical practiceDuring the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in clinical practice, with a focus on patient-specific considerations in the development of personalized treatment plans. To open, Hermann Einsele provides a presentation reviewing the latest data from trials of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma (RRMM), including the KarMMa and CARTITUDE trials. He explores criteria for the identification of patients who may benefit from CAR T-cell therapy, mechanisms of resistance to BCMA CAR T-cell therapy, and t...2024-07-1645 min
VJHemOnc PodcastDetermining the optimal sequencing of bispecifics and CAR-T cells in multiple myelomaBispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents.
In this podcast, experts Salomon Manier, MD, PhD, Lille University Hospital, Lille, France, Surbhi Sidana, MD, Stanford University, Stanford, CA, and Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, share some interesting insights into the optimal sequencing of bispecific antibodies and CAR-T cells in myeloma, highlighting data from recent cl...2023-08-0307 min
VJHemOnc PodcastDetermining the optimal sequencing of bispecifics and CAR-T cells in multiple myelomaBispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents.
In this podcast, experts Salomon Manier, MD, PhD, Lille University Hospital, Lille, France, Surbhi Sidana, MD, Stanford University, Stanford, CA, and Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, share some interesting insights into the optimal sequencing of bispecific antibodies and CAR-T cells in myeloma, highlighting data from recent cl...2023-08-0307 min
CME in Minutes: Education in Primary CareHermann Einsele, MD - Interpreting the Latest Data for Emerging B-Cell Maturation Antigen–Targeted Combination Treatment Strategies for Patients With Multiple Myeloma: Clinical Perspectives From 2022Please visit answersincme.com/ZWK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology and oncology discusses B-cell maturation antigen (BCMA)–targeted strategies for the treatment of multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the latest evidence for investigational regimens containing BCMA-targeted immunotherapies for earlier lines of multiple myeloma (MM) treatment; Evaluate the clinical impact of combining late-stage emerging, BCMA-targeted strategies with standard of care (SOC) for earlier lines of MM treatment; and Identify strategies to optimally incorporate novel BCMA-containing therapies in...2023-01-1015 min
CME in Minutes: Education in Oncology & HematologyHermann Einsele, MD - Interpreting the Latest Data for Emerging B-Cell Maturation Antigen–Targeted Combination Treatment Strategies for Patients With Multiple Myeloma: Clinical Perspectives From 2022Please visit answersincme.com/ZWK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology and oncology discusses B-cell maturation antigen (BCMA)–targeted strategies for the treatment of multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the latest evidence for investigational regimens containing BCMA-targeted immunotherapies for earlier lines of multiple myeloma (MM) treatment; Evaluate the clinical impact of combining late-stage emerging, BCMA-targeted strategies with standard of care (SOC) for earlier lines of MM treatment; and Identify strategies to optimally incorporate novel BCMA-containing therapies in...2023-01-1015 minHämatologie ShortcastsMultiples MyelomIn der heutigen Folge besprechen wir das Multiple Myelom. Wir freuen uns Prof. Dr. med. Hermann Einsele als Gastredner begrüßen zu dürfen. Sie haben Fragen, Anmerkungen oder Kritik? Senden Sie uns eine Mail an info@ng-akademie.de.
Besuchen Sie gerne unsere Website, um mehr zu erfahren. Dort finden Sie weitere Informationen zu unserem Podcast und können vergangene Folgen anhören.Hören Sie auch in die Onkologie Shortcasts, dem Podcast zu soliden Tumoren.Falls Sie Fragen, Anmerkungen oder Kritik...2022-10-261h 05VJHemOnc PodcastT-cell engagers in multiple myeloma: current challenges and future outlooksSeveral novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of this disease. However, relapse is still common in many patients, and there is a need to continue exploring novel therapeutic strategies. The introduction of immunotherapies, including CAR-T cell therapy and bispecific T-cell engagers, has marked a paradigm shift in the treatment of multiple myeloma, and T-cell based therapies have shown promising outcomes.
In this exclusive podcast, leading experts Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, Nina Shah, MD, University of California, San Francisco, CA...2022-08-2420 minVJHemOnc PodcastT-cell engagers in multiple myeloma: current challenges and future outlooksSeveral novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of this disease. However, relapse is still common in many patients, and there is a need to continue exploring novel therapeutic strategies. The introduction of immunotherapies, including CAR-T cell therapy and bispecific T-cell engagers, has marked a paradigm shift in the treatment of multiple myeloma, and T-cell based therapies have shown promising outcomes.
In this exclusive podcast, leading experts Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, Nina Shah, MD, University of California, San Francisco, CA...2022-08-2420 min
Multiples zum Myelom mit Leo RascheImmuntherapien beim Myelom: Entwicklung, Durchbruch und zukünftige ChancenIn Episode 8 des Podcasts „Multiples zum Myelom“ widmen sich Dr. Leo Rasche und sein Gast Prof. Hermann Einsele (Universitätsklinikum Würzburg) der Immuntherapie beim Myelom. Aktuelle Studien zu bispezifischen Antikörpern und CAR-T-Zellen zeigen selbst bei intensiv vorbehandelten Patient*innen hohe Ansprechraten. Wie schätzen die beiden Experten die Zukunft dieser neuen Therapien ein? 2022-04-0116 minVJHemOnc PodcastCAR-T vs bispecifics: replacing ASCT in myelomaAutologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades; however, high-risk patients still have poor outcomes. Many bispecific antibody therapies are currently under investigation for the treatment of myeloma, such as blinatumomab, teclistamab, talquetamab and cevostamab, and the chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel, became the first CAR-T therapy to receive FDA approval for the treatment of multiple myeloma in March 2021. With CAR-T and bispecific antibodies demonstrating deep and sustained remissions, the role of ASCT in the future treatment of myeloma has become a subject of...2021-09-1710 minVJHemOnc PodcastCAR-T vs bispecifics: replacing ASCT in myelomaAutologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades; however, high-risk patients still have poor outcomes. Many bispecific antibody therapies are currently under investigation for the treatment of myeloma, such as blinatumomab, teclistamab, talquetamab and cevostamab, and the chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel, became the first CAR-T therapy to receive FDA approval for the treatment of multiple myeloma in March 2021. With CAR-T and bispecific antibodies demonstrating deep and sustained remissions, the role of ASCT in the future treatment of myeloma has become a subject of...2021-09-1710 minMultiple Myeloma HubMy experience with novel immunotherapiesDuring the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, University of Würzburg, Würzburg, DE, about novel immunotherapies.Bispecific antibodies and chimeric antigen receptor (CAR) T cells represent a novel interesting therapeutic option for patients with multiple myeloma. In this podcast, after explaining their mechanism of action, Hermann Einsele gives an overview of the major findings from clinical trials evaluating efficacy and safety of bispecific antibodies and CAR T cells. The advantage of bispecific antibodies in co...2020-11-1111 min